0001193125-25-328822 | 6-K | XBRL Viewer

Principal Accounting Policies

6 Months Ended

Jun. 30, 2025

Disclosure of Summary of Significant Accounting Policies [Abstract]

PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated interim financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values.

Other than additional accounting policies resulting from application of amendments to IFRSs, and the application of IFRS 15, Revenue from Contracts with Customers, the accounting policies and methods of computation used in the unaudited condensed consolidated interim financial statements for the six months ended June 30, 2024 and 2025 are the same as those presented in the Group’s annual financial statements for the year ended December 31, 2024.

Application of amendments to IFRSs

For the purposes of preparing and presenting the unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025, the Group has applied the following amendments to IFRSs issued by the IASB, for the first time, which are mandatorily effective for the Group’s annual period beginning on January 1, 2025:


Amendments to IFRS 3	Reference to the Conceptual Framework
Amendments to IAS 16	Property, Plant and Equipment: Proceeds before Intended Use
Amendments to IAS 21	The Effects of Changes in Foreign Exchange Rates
IFRIC agenda decision	Guarantees Issued on Obligations of Other Entities

The application of the amendments to IFRSs in the current interim period has had no material impact on the Group’s financial position and performance for the current and prior periods and/or on the disclosures set out in these unaudited condensed consolidated interim financial statements.

New standards, amendments and interpretations not yet adopted by the Group

Certain standards, amendments and interpretations have been published through the June 30, 2025 reporting period and have not been early adopted by the Group. These are as follows:

•

Presentation and Disclosure in Financial Statements (IFRS 18 Presentation and Disclosure in Financial Statements (“IFRS 18”)); and

•

Annual Improvements to IFRS Accounting Standards - Volume 11;

The Group is in the process of analyzing the impact of the above.

IFRS 15, Revenue from contracts with customers

The Group may enter into collaboration and licensing arrangements for research and development, manufacturing, and commercialization activities with counterparties for the development and commercialization of its product candidates. These arrangements may contain multiple components, such as (i) licenses, and (ii) the manufacturing of certain materials. Payments pursuant to these arrangements may include non-refundable payments, payments upon the achievement of significant regulatory, development and commercial milestones, sales of product at certain agreed-upon amounts, and royalties on product sales.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration or license agreement, the Group performs the following steps for agreements that are in scope of IFRS 15 Revenue from contracts with customers (“IFRS 15”): (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii)

measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Group satisfies each performance obligation.

The Group must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates and probabilities of regulatory and commercial success. The Group also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition and future reversal of variable consideration.

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2025
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Entity Registrant Name	Apollomics Inc.
Entity Central Index Key	0001944885
Current Fiscal Year End Date	--12-31
Entity File Number	001-41670
Entity Address, Address Line One	989 E. Hillsdale Blvd., Suite 220
Entity Address, City or Town	Foster City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94404

Label

Element

Value

Reserves

aplm_Reserves

$ 42,422,000

Reserves

aplm_Reserves

$ 39,148,000

Shares Issued To PIPE Investors, Net Of Transaction Costs Shares

aplm_SharesIssuedToPipeInvestorsNetOfTransactionCostsShares

191,667

Shares Issued To PIPE Investors, Net Of Transaction Costs

aplm_SharesIssuedToPipeInvestorsNetOfTransactionCosts

$ 2,000

Shares Issued To PIPE Investors, Net Of Transaction Costs

aplm_SharesIssuedToPipeInvestorsNetOfTransactionCosts

5,047,000

Shares Issued To PIPE Investors, Net Of Transaction Costs

aplm_SharesIssuedToPipeInvestorsNetOfTransactionCosts

$ 5,049,000

Shares Issued To Employees For Compensation Shares

aplm_SharesIssuedToEmployeesForCompensationShares

12,386

Shares Issued To Employees For Compensation

aplm_SharesIssuedToEmployeesForCompensation

$ 1,506,000

Shares Issued To Employees For Compensation

aplm_SharesIssuedToEmployeesForCompensation

$ 1,506,000

Shares Issued To Board Members For Board Fees Shares

aplm_SharesIssuedToBoardMembersForBoardFeesShares

693

Shares Issued To Board Members For Board Fees Shares

aplm_SharesIssuedToBoardMembersForBoardFeesShares

556

Adjustments For Depreciation Of Plant And Equipment

aplm_AdjustmentsForDepreciationOfPlantAndEquipment

$ 18,000

Adjustments For Depreciation Of Plant And Equipment

aplm_AdjustmentsForDepreciationOfPlantAndEquipment

25,000

Adjustments For Amortization Of Right Of Use Assets

aplm_AdjustmentsForAmortizationOfRightOfUseAssets

115,000

Adjustments For Amortization Of Right Of Use Assets

aplm_AdjustmentsForAmortizationOfRightOfUseAssets

164,000

Adjustments To Right-Of-Use Assets And Associated Lease Liabilities Write-Off

aplm_AdjustmentsToRight-Of-UseAssetsAndAssociatedLeaseLiabilitiesWrite-Off

7,000

Adjustments for Fair Value Change of Financial Liabilities at FVTPL

aplm_AdjustmentsForFairValueChangeOfFinancialLiabilitiesAtFvtpl

384,000

Adjustments for Fair Value Change of Financial Liabilities at FVTPL

aplm_AdjustmentsForFairValueChangeOfFinancialLiabilitiesAtFvtpl

(164,000)

Adjustments For Increase Decrease In Deposits Prepayments And Deferred Expenses And Accounts Receivable

aplm_AdjustmentsForIncreaseDecreaseInDepositsPrepaymentsAndDeferredExpensesAndAccountsReceivable

(7,541,000)

Adjustments For Increase Decrease In Deposits Prepayments And Deferred Expenses And Accounts Receivable

aplm_AdjustmentsForIncreaseDecreaseInDepositsPrepaymentsAndDeferredExpensesAndAccountsReceivable

(375,000)

Adjustments For Increase Decrease In Other Payables And Accruals And Other Non Current Liabilities

aplm_AdjustmentsForIncreaseDecreaseInOtherPayablesAndAccrualsAndOtherNonCurrentLiabilities

7,095,000

Adjustments For Increase Decrease In Other Payables And Accruals And Other Non Current Liabilities

aplm_AdjustmentsForIncreaseDecreaseInOtherPayablesAndAccrualsAndOtherNonCurrentLiabilities

1,319,000

Refund of Rental Deposits Classified As Investing Activities

aplm_RefundOfRentalDepositsClassifiedAsInvestingActivities

6,000

Proceeds From Pipe Financings Net Of Transaction Costs

aplm_ProceedsFromPipeFinancingsNetOfTransactionCosts

5,049,000

Repayments of bank loans

aplm_RepaymentsOfBankLoans

1,412,000

Proceeds From Bank Loans

aplm_ProceedsFromBankLoans

702,000

Reconciliation Of Movement In Lease Right Of Use Assets And Associated Lease Liabilities

aplm_ReconciliationOfMovementInLeaseRightOfUseAssetsAndAssociatedLeaseLiabilities

142,000

Reconciliation Of Movement In Lease Right Of Use Assets And Associated Lease Liabilities

aplm_ReconciliationOfMovementInLeaseRightOfUseAssetsAndAssociatedLeaseLiabilities

911,000

Restricted Stock And Stock Options Issued In Lieu Of Accrued Compensation Non Cash Activities

aplm_RestrictedStockAndStockOptionsIssuedInLieuOfAccruedCompensationNonCashActivities

$ 1,506,000

Date Of Incorporation

aplm_DateOfIncorporation

Jan. 14, 2016

Date Of Incorporation

aplm_DateOfIncorporation

Nov. 04, 2016

Date Of Incorporation

aplm_DateOfIncorporation

Jun. 24, 2019

Date Of Incorporation

aplm_DateOfIncorporation

May 29, 2018

Date Of Incorporation

aplm_DateOfIncorporation

May 29, 2020

Date Of Incorporation

aplm_DateOfIncorporation

Aug. 19, 2022

Disclosure Of Loss For The Year Explanatory

aplm_DisclosureOfLossForTheYearExplanatory

loss for the period


	For the six months ended June 30,
	2025		2024
(In thousands)
Loss for the period has been arrived at after charging:
Staff costs:
Salaries and other allowances	$	1,320	$	4,677
Retirement benefits scheme contributions		36		290
Share-based payment expenses		3,274		8,224
Total staff costs		4,630		13,191
Depreciation of plant and equipment		18		25
Amortization of right-of-use assets		115		164
Amortization of intangible assets		10		10
Impairment loss of intangible assets		1,500		10,000
Other expenses		14		90

Disclosure Of Detailed Information About Loss After Charging Expenses Explanatory

aplm_DisclosureOfDetailedInformationAboutLossAfterChargingExpensesExplanatory


	For the six months ended June 30,
	2025		2024
(In thousands)
Loss for the period has been arrived at after charging:
Staff costs:
Salaries and other allowances	$	1,320	$	4,677
Retirement benefits scheme contributions		36		290
Share-based payment expenses		3,274		8,224
Total staff costs		4,630		13,191
Depreciation of plant and equipment		18		25
Amortization of right-of-use assets		115		164
Amortization of intangible assets		10		10
Impairment loss of intangible assets		1,500		10,000
Other expenses		14		90

Salaries And Other Allowances

aplm_SalariesAndOtherAllowances

$ 1,320,000

Salaries And Other Allowances

aplm_SalariesAndOtherAllowances

4,677,000

Amortization of rightofuse assets

aplm_AmortizationOfRightofuseAssets

115,000

Amortization of rightofuse assets

aplm_AmortizationOfRightofuseAssets

$ 164,000

Disclosure Of Detailed Information About Anti Dilutive Securities Excluded From Computation Earnings Per Share Exlanatory

aplm_DisclosureOfDetailedInformationAboutAntiDilutiveSecuritiesExcludedFromComputationEarningsPerShareExlanatory

The diluted loss per share for the six months ended June 30, 2024 and 2025 does not include the effect of the following instruments held as of June 30, 2024 and 2025 as their inclusion would be anti-dilutive:


	As of June 30,
(In thousands)	2025		2024
Unvested restricted shares		5		364
Share options		256		24,167
Apollomics Private Warrants		619		619
Apollomics Public Warrants		10,350		10,350
Penny Warrants		8		58

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amounts